Get the Stockscreener App
6.64
0.15%
-0.02
Fennec Pharmaceuticals Inc stock is traded at $6.64, with a volume of 53,402.
It is down -0.15% in the last 24 hours and up +9.02% over the past month.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
See More
Previous Close:
$6.66
Open:
$6.65
24h Volume:
53,402
Relative Volume:
0.49
Market Cap:
$181.46M
Revenue:
$21.25M
Net Income/Loss:
$-16.05M
P/E Ratio:
-10.89
EPS:
-0.61
Net Cash Flow:
$-17.14M
1W Performance:
+2.31%
1M Performance:
+9.02%
6M Performance:
+15.45%
1Y Performance:
-33.63%
1-Day Range:
$6.50
$6.79
1-Week Range:
$6.30
$6.86
52-Week Range:
$3.96
$11.49
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Name
Fennec Pharmaceuticals Inc
Sector
Industry
Phone
(919) 636-4530
Address
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
6.665 | 181.46M | 21.25M | -16.05M | -17.14M | -0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.10 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
712.14 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
647.00 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.79 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.73 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Aug-08-22 | Resumed | Craig Hallum | Buy |
| Jun-05-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-11-18 | Initiated | Goldman | Buy |
Fennec Pharmaceuticals Inc Stock (FENC) Latest News
Fennec Pharmaceuticals Inc. - Baystreet.ca
Fennec Pharmaceuticals Announces Commercial Launch of Pedmarqsi in Germany - Marketscreener.com
Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany - The Manila Times
Fennec Pharmaceuticals Brief: Announcing Commercial Launch of PEDMARQSI In Germany - Marketscreener.com
Revolutionary Cancer Drug PEDMARQSI Now Available in Germany$273M Deal Potential - StockTitan
Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells $66,600.00 in Stock - MarketBeat
Fennec Pharmaceuticals director Raykov sells $66,600 in shares - MSN
Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov Sells 2,431 Shares - MarketBeat
Insider Sell Alert: Rosty Raykov Sells 10,000 Shares of Fennec P - GuruFocus.com
Fennec Pharmaceuticals director Raykov sells $66,600 in shares By Investing.com - Investing.com Nigeria
Fennec Pharmaceuticals Inc (NASDAQ:FENC) Sees Large Decrease in Short Interest - MarketBeat
Fennec Pharmaceuticals (TSE:FRX) Stock Price Passes Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Trend Tracker for (FENC) - Stock Traders Daily
Fennec PharmaA Sound Investment? - RTTNews
Fennec Pharmaceuticals (NASDAQ:FENC) shareholder returns have been respectable, earning 41% in 3 years - Simply Wall St
Fennec Pharmaceuticals (NASDAQ:FENC) versus CARGO Therapeutics (NASDAQ:CRGX) Financial Survey - Defense World
Fennec Pharmaceuticals (TSE:FRX) Stock Price Crosses Below 50-Day Moving AverageWhat's Next? - MarketBeat
Barclays PLC Raises Holdings in Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
Learn to Evaluate (FENC) using the Charts - Stock Traders Daily
Fennec Pharmaceuticals Inc. (TSE:FRX) Director Sells C$87,552.00 in Stock - MarketBeat
Barclays PLC Grows Position in Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
Rosty Raykov Sells 10,000 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock - MarketBeat
Fennec Pharmaceuticals director Raykov Rosty sells $60,800 in shares By Investing.com - Investing.com Australia
Fennec Pharmaceuticals director Raykov Rosty sells $60,800 in shares - Investing.com
Franklin Resources Inc. Has $74,000 Holdings in Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
State Street Corp Has $1.64 Million Stake in Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
Fennec Pharmaceuticals (TSE:FRX) Shares Pass Above 50 Day Moving AverageShould You Sell? - MarketBeat
Stocks In Play: Fennec Pharmaceuticals Inc. - Barchart
(FENC) Trading Advice - Stock Traders Daily
Wedbush Raises Earnings Estimates for Fennec Pharmaceuticals - Defense World
Q4 EPS Estimate for Fennec Pharmaceuticals Raised by Analyst - MarketBeat
Wedbush Issues Optimistic Outlook for TSE:FRX Earnings - Defense World
Equities Analysts Issue Forecasts for TSE:FRX Q3 Earnings - MarketBeat
Fennec Pharmaceuticals Announces Pedmarqsi Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales - Marketscreener.com
Fennec Pharmaceuticals Inc. (TSE:FRX) Director Acquires C$96,840.00 in Stock - MarketBeat
Fennec Pharmaceuticals’ (FENC) Outperform Rating Reiterated at Wedbush - Defense World
Fennec's Pedmarqsi gets nod from U.K. regulators - MSN
Long Term Trading Analysis for (FENC) - Stock Traders Daily
Fennec Pharmaceuticals (NASDAQ:FENC) Receives Outperform Rating from Wedbush - MarketBeat
Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales - The Manila Times
Fennec's PEDMARQSI® Breakthrough: First NHS Treatment for Child Cancer-Related Hearing Loss - StockTitan
HC Wainwright Issues Negative Forecast for TSE:FRX Earnings - Defense World
What is HC Wainwright’s Forecast for FENC FY2024 Earnings? - Defense World
FY2024 Earnings Estimate for TSE:FRX Issued By HC Wainwright - MarketBeat
What is HC Wainwright's Estimate for FENC FY2024 Earnings? - MarketBeat
Fennec Pharmaceuticals partially repays its outstanding convertible debt facility - MSN
Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management - The Manila Times
Verition Fund Management LLC Sells 23,113 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
Fennec Pharmaceuticals' (FENC) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Fennec Pharmaceuticals Inc Stock (FENC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):